COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01416623
Recruitment Status : Terminated
First Posted : August 15, 2011
Last Update Posted : December 21, 2012
Information provided by (Responsible Party):
Jiangsu HengRui Medicine Co., Ltd.

Brief Summary:
Henatinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study is designed to evaluate the safety and tolerability of Henatinib in patients with Advanced Solid Malignancies

Condition or disease Intervention/treatment Phase
Advanced Solid Cancer Drug: henatinib Phase 1

Detailed Description:
  1. To evaluate the safety and tolerability of Henatinib, and the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT).
  2. To determine the pharmacokinetic profile of Henatinib and its metabolites .
  3. To assess preliminary antitumor activity .
  4. To determine preliminary regimen for phase II study .

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 44 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies
Study Start Date : September 2010
Estimated Primary Completion Date : December 2012
Estimated Study Completion Date : December 2012

Arm Intervention/treatment
Experimental: Henatinib
Henatinib either at 12.5,25,37.5,50,62.5,75,87.5 or 100 mg, p.o. once daily
Drug: henatinib
Henatinib Maleate Tablets

Primary Outcome Measures :
  1. The maximum-tolerated dose (MTD) regimen of henatinib will be defined as the maximum dose level at which no more than one subject out of six experiences a dose-limiting toxicity (DLT) after completing one treatment cycle. [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: 8 weeks ]
  2. Henatinib pharmacokinetic parameters may include AUC, Cmax, Tmax, and t1/2. [ Time Frame: 4 weeks ]
  3. Objective response rate (ORR) [ Time Frame: 8 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histologically or cytologic (except sputum smear) confirmed metastatic or locally advanced solid tumor (At least one measurable lesion longest diameter ≥20 mm using conventional techniques or larger than 10 mm in diameter by spiral CT scan).
  2. Life expectancy of more than 12 weeks.
  3. Lack of standard treatment or standard treatment failure.
  4. Screening laboratory values within the following parameters:

    1. HB:≥90g/L
    2. ANC:≥1.5×109/L
    3. PLT:≥100×109/L
  5. ALT and AST:≤1.5×ULN(But if the liver metastases, ALT and AST:≤5×ULN) 1. Serum total bilirubin:≤1.5×ULN 2. Serum creatinine:≤1.5×ULN 3. Creatinie clearance rate:≥60ml/min 4. Electrolytes normal or return to normal after treatment
  6. Recovery from all clinically significant AEs related to prior therapies. Duration from the latest therapy is more than 6 weeks for nitroso or mitomycin, or more than 4 weeks for radiotherapy, chemotherapy, immunotherapy or other anti-cancer treatments (such as testing drugs, biologics, hormones or surgery).
  7. Signed and dated informed consent. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.

Exclusion Criteria:

  1. Evidence of CNS metastasis.
  2. Major surgery, open biopsy, or obvious trauma within 4 weeks before treatment.
  3. Obvious peritoneal implantation or pelvic obstruction.
  4. II level or above, peripheral neuropathy (NCI CTC AE v3.0).
  5. Known history of neurological or psychiatric disease.
  6. Suffering from high blood pressure and can not be reduced to the following range by monotherapy (systolic blood pressure <140 mmHg, diastolic blood pressure <90 mmHg).
  7. History of heart disease:> NYHA II class congestive heart failure; unstable coronary artery disease (patients who had last myocardial infarction 12 months before can be enrolled), arrhythmias - requires antiarrhythmic drug therapy. Bazett's corrected QTc ≥ 480 ms or can not be measured. (Note: If ECG QTc interval ≥ 480 ms during the screening period, you must repeat 2 times, separated by at least 24 hours, the average QTc of the 3 times must be <480 s, the patient can be enrolled in this study) .
  8. Coagulopathy (PT> 16 s, APTT> 43 s, TT> 21 s, Fbg <2 g / L), with a bleeding tendency or are receiving the therapy of thrombolysis or anticoagulation.
  9. Confirmed active gastrointestinal ulcers.
  10. Active severe infection (> NCI-CTC 3.0 standard 2).
  11. Patients with severe epilepsy requires drug treatment (such as steroids or anti-epileptic drugs).
  12. Other serious illness or condition.
  13. Treated with VEGFR TKIs such as sunitinib or solafenib before study entry.
  14. Less than 4 weeks from the last clinical trial.
  15. Pregnancy, breast-feeding women or women of childbearing age without effective contraception.
  16. Allergic or known history of hypersensitivity to henatinib or any of it components.
  17. Drug abuse, the drug and mental illness may affect the patients participation in this study and the assessment of the research results.
  18. Any unstable or likely situation that harms the safety and compliance of the patients in this study.
  19. Any factors that influence the usage of oral administration.
  20. Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01416623

Layout table for location information
China, Shanghai
Fudan University Shanghai Cancer Center
Shanghai, Shanghai, China, 200032
Sponsors and Collaborators
Jiangsu HengRui Medicine Co., Ltd.
Layout table for investigator information
Principal Investigator: jin Li, Dr Fudan University
Layout table for additonal information
Responsible Party: Jiangsu HengRui Medicine Co., Ltd. Identifier: NCT01416623    
Other Study ID Numbers: HNTN-I
First Posted: August 15, 2011    Key Record Dates
Last Update Posted: December 21, 2012
Last Verified: December 2012
Keywords provided by Jiangsu HengRui Medicine Co., Ltd.:
Advanced solid cancer
phase I
Additional relevant MeSH terms:
Layout table for MeSH terms